ArriVent BioPharma, Inc. Stock Analysis & AI Score
ArriVent BioPharma, Inc. (AVBP) has an ST Score of 61.0 (B), driven by its Financial Strength (A+) and held back by its Growth (C+). Analysts rate it Buy with a $46.00 price target (+52.8% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
ArriVent BioPharma, Inc. (AVBP) has an ST Score of 61.0 (B), driven by its Financial Strength (A+) and held back by its Growth (C+). Analysts rate it Buy with a $46.00 price target (+52.8% upside).
- Strongest
- Financial StrengthA+
- Weakest
- GrowthC+
All factor grades
- Financial StrengthA+
- ValuationA-
- MomentumB+
- ForecastB
- ProfitabilityC+
- GrowthC+
- Piotroski2/9
Contact
AVBP stock: frequently asked questions
What is AVBP's ST Score?
ArriVent BioPharma, Inc. (AVBP) has an ST Score of 61.0 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is AVBP a buy, hold, or sell?
Analysts rate AVBP a Buy, with a price target of $46.00 (+52.8% vs the current price). Our ST Score grades it B (61.0/100). The ST Score is a data-driven signal, not a recommendation.
What are AVBP's factor grades?
Valuation A-, Profitability C+, Financial Strength A+, Momentum B+, Growth C+, Forecast B.
What is AVBP's valuation grade?
ArriVent BioPharma, Inc. (AVBP) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is AVBP's growth grade?
ArriVent BioPharma, Inc. (AVBP) earns a growth grade of C+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is AVBP's profitability grade?
ArriVent BioPharma, Inc. (AVBP) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is AVBP's financial strength grade?
ArriVent BioPharma, Inc. (AVBP) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for AVBP?
The average analyst price target for ArriVent BioPharma, Inc. (AVBP) is $46.00 from 8 analysts, which is +52.8% versus the recent price of $30.10.
What is AVBP's Piotroski score?
ArriVent BioPharma, Inc. (AVBP) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.